Of 12 muscle peptides, only tesamorelin has phase III trial data — visceral fat -18%, IGF-1 +80%. Every option ranked by mechanism, evidence, and cost.
For readers searching "best peptides for muscle growth," the short answer most experienced users describe in community sources is this: muscle-focused peptides are typically run as a pair, not a single compound. One peptide signals the brain to make growth hormone; a second triggers release. Published clinical research describes the combination as producing a GH pulse 2-3x larger than either peptide alone — which is why pairs and pre-mixed blends dominate community usage.
Research-context information only. Peptides discussed below are research compounds. Protocols, doses, and reactions reported come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
Evidence at a glance
Peptides covered below, sorted by clinical evidence strength. Each peptide also carries a parallel community-evidence grade reflecting real-world adoption. How we grade evidence.
Animal hypertrophy data; no human RCTs in healthy trained populations.
This guide ranks the 12 peptides community sources most commonly describe for muscle, in the order experienced users typically reach for them. Each entry explains what trial data and community usage describe for that peptide in a muscle context, who typically chooses it, and what self-reported community outcomes look like. Dosing, injection timing, and bloodwork details live in the linked deep-dive guides.
The Rankings
Bac Water Made for Peptides50% off
Don't risk a $300 peptide on generic bac water.
Most cloudy reconstitutions trace back to one thing — and it isn't the peptide. Sterile, non-pyrogenic, 0.9% benzyl alcohol — formulated for peptide reconstitution, not repackaged from generic stock.
✓ 0.9% benzyl alcohol✓ Made for peptides✓ 30 mL multi-dose
1. Tesamorelin + Ipamorelin (Blend) — the premium recomp stack
Best for: lifters who want both visible muscle gain and a smaller waistline in the same cycle.
This is the stack many community users describe graduating to once they've experienced lower-tier GH peptides. Tesamorelin is the most clinically-tested compound on this entire list — the only GHRH analog with phase III randomized trial data behind it. A 26-week trial in patients with abdominal fat accumulation reported daily tesamorelin reducing visceral fat by roughly 15-18% and raising IGF-1 about 80% versus placebo. A follow-up analysis of the same trials reported tesamorelin also increased truncal lean muscle area while decreasing intramuscular fat. The clinical translation: less fat below the surface, denser muscle composition above it.
Ipamorelin is the GHRP that pairs with it. Trial data describe it as the most selective GHRP — releasing growth hormone without meaningful cortisol, ACTH, or prolactin elevation. That selectivity is what makes pre-bed dosing compatible with normal sleep architecture in published research.
Community reports on tesa + ipa cluster around three themes: visible waist-tightening within 4-6 weeks, deeper sleep within the first week, and improved between-session recovery. The most common complaints in those same community sources are cost (it's the most expensive stack on this list) and occasional injection-site sensitivity attributed to tesamorelin specifically.
2. CJC-1295 (no DAC) + Ipamorelin (Blend) — the canonical starter stack
Best for: users running their first GH peptide protocol and looking for the most commonly chosen entry point.
Community sources commonly describe CJC + ipa (specifically the no-DAC version of CJC-1295, sometimes called "mod GRF 1-29") as the default opening stack — affordability, broad vendor availability, and consistent self-reported outcomes are the three reasons cited most often.
CJC-1295 is a synthetic GHRH analog modified to extend its half-life in the bloodstream — about 30 minutes versus the few-minute window of native GHRH. Published pharmacokinetic data describe that window as long enough to produce a meaningful GH pulse when paired with a GHRP, and short enough to preserve the pulsatile rhythm of natural GH release rather than flatten it. A single injection in healthy adults raised GH 2-10x and IGF-1 1.5-3x in published research.
Combined with ipamorelin, the stack produces a clean synergistic pulse — the same mechanism described for tesa + ipa, at a lower price point and with somewhat less direct outcome data.
Community reports on CJC + ipa cluster around consistent themes: better sleep within days, fuller-looking muscles around week 3-4, and gradual fat loss alongside slow recomposition by week 8. The most common caveat in those same community sources is that the effects feel subtle relative to tesa + ipa — not weak, but smaller in magnitude. Users who have run both commonly describe tesa as producing larger body-composition shifts at higher doses, with the trade-off of higher overall cost.
Best for: people who already have a preferred GHRP and just want to add the strongest GHRH.
Tesamorelin alone still produces meaningful GH elevation — trial data describe it as the strongest GHRH analog on a per-mg basis, and it's the only one with phase III evidence for both fat-loss and lean-mass effects. Users already running ipamorelin or another GHRP commonly add tesamorelin separately rather than buying the blend, which gets close to the #1 stack at a different cost structure.
Where solo tesa falls short of the blend: two separate vials, two separate draws, and the two peptides need to be timed tightly enough to overlap for the GH-pulse synergy. Community usage of solo tesa skews toward users who either already had ipamorelin on hand or wanted finer dose control on each component than a fixed blend allows.
Best for: budget-conscious starters who want to mix their own stack rather than buy a blend.
Same compound as #2, just sold as a single vial instead of pre-mixed with ipamorelin. The case for buying it solo is mostly about price flexibility — singles are sometimes cheaper than the blend depending on the vendor and current promos, and the GHRP partner can be matched to the goal (ipamorelin for clean recomp, GHRP-6 for hard-gainer appetite, GHRP-2 for raw pulse strength).
The case against: extra reconstitution, extra arithmetic, and if you mis-mix the ratio you lose the synergy. For most people the blend at #2 is the simpler default.
Best for: people already on a GHRH (often via a telehealth clinic) who need the matching release peptide.
Ipamorelin's claim to fame is that it doesn't do the things other GHRPs do badly — no cortisol spike, no prolactin bump, no aggressive appetite increase, no impact on sleep architecture. It's the most "boring" peptide on this list in the best possible way: it lifts growth hormone and gets out of the way.
Solo ipamorelin for muscle is uncommon in community usage — the ghrelin-receptor pulse on its own is smaller in published research than the combined GHRH+GHRP pulse. The use case in community sources is users already on sermorelin, tesamorelin, or CJC-1295 from a clinic who need to add the GHRP half to complete the stack.
Community feedback is consistent: people on a GHRH-only protocol who add ipamorelin almost always notice a real step up in sleep quality and recovery within the first week.
Best for: experienced users who want the convenience of a once-or-twice-weekly injection and accept the trade-offs.
The DAC version of CJC-1295 is the same molecule with an added "drug affinity complex" that binds to serum albumin, stretching the half-life to about 8 days. That's a very different pharmacological profile than the no-DAC version — instead of a sharp pulse and rest, the result is sustained, non-pulsatile GH elevation. Convenient (fewer injections), but the lack of pulsatility is a documented issue: community reports commonly describe more side effects (water retention, mild carpal tunnel symptoms, joint stiffness) and a less pronounced recomposition effect than with no-DAC.
The most common community sentiment is that DAC is "easier to run, harder to like." For pure muscle growth, the no-DAC version usually wins. DAC's niche is anti-aging or once-weekly clinic protocols where the convenience matters more than maximum pulse.
Best for: users over 40 looking for the gentlest, most well-established GHRH on the list.
Sermorelin was the original synthetic GHRH and was FDA-approved decades ago for pediatric GH deficiency before that approval was withdrawn for commercial reasons (not safety findings). It has the longest clinical track record of any peptide on this list. The trade-off in published pharmacokinetic data: a short half-life means each pulse is smaller per dose than CJC-1295 or tesamorelin.
That smaller pulse is also why sermorelin remains common among older users and those prioritizing the most physiological, lowest-side-effect GHRH option. Community sources commonly describe sermorelin + ipamorelin as the conservative on-ramp for users new to GH peptides who want the gentlest possible introduction.
Community reports for sermorelin cluster around subtle sleep improvements, gradual recovery improvements, and modest body-composition shift over longer time horizons. Users who switch from sermorelin to CJC + ipa typically describe a noticeable difference, while others self-report running sermorelin long-term without issue.
Best for: people who want maximum GH per injection and don't mind the off-target effects.
GHRP-2 produces a stronger GH pulse per mg than ipamorelin. The catch is that it's not selective — it also raises cortisol, ACTH, and prolactin, and it bumps appetite enough to notice. For someone in a calorie surplus trying to add mass, the appetite signal is a feature. For someone cutting, it's a problem.
Like all GHRPs, GHRP-2 needs a GHRH partner (CJC-1295, sermorelin, or tesamorelin) to deliver its full effect. Solo GHRP-2 is rare in muscle-focused protocols because you're leaving half the synergy on the table.
The community split on GHRP-2 is real: some users love the bigger pulse and don't notice the side effects, others find the cortisol/prolactin shift unsettling within days. If you've tried ipamorelin and felt the response was too subtle, GHRP-2 is the obvious next step. If you're price-shopping and don't care about selectivity, it's also usually cheaper.
Best for: hard-gainers who specifically want the appetite push that comes with it.
GHRP-6 has the biggest hunger signal of any peptide on this list. That's the entire reason to choose it. If you're a naturally lean person who struggles to eat enough to grow, GHRP-6 + a GHRH like CJC-1295 turns "I can't get the calories in" into "I can't stop eating." For everyone else — anyone cutting, anyone trying to recomp, anyone with appetite already dialed in — it's the wrong tool.
GH release is broadly similar to GHRP-2, but the appetite effect dominates the user experience. Community reports are blunt: people on GHRP-6 either love it for the calorie support or stop quickly because the hunger is unmanageable.
Best for: users who don't want to inject and accept the side-effect profile that comes with daily oral dosing.
MK-677 is the only oral compound on this list. It activates the same ghrelin receptor as the GHRPs but in pill form, taken once daily in trial protocols. A 12-month randomized trial in older adults reported significant gains in fat-free mass with daily MK-677, though strength did not move significantly over that window. The clinical translation: trial subjects gained mass, but the gains were largely compositional (water retention, fuller-looking muscles, higher scale weight) rather than functional (raw strength).
The side-effect profile is what keeps MK-677 from ranking higher. The most consistent community-reported complaints are noticeable water retention by week 2, sharp appetite increase that some users tolerate and others find unmanageable, and measurable elevation in fasting blood glucose. Trials and community sources flag fasting-glucose drift as the most consistent caution, particularly for users with insulin resistance or pre-diabetes — community-recommended bloodwork protocols treat the 8-week glucose check as non-negotiable.
For users who can't or won't inject, MK-677 is a real option. For others, the injectable stacks generally produce cleaner results in both trial data and community reports.
Best for: advanced users who've already optimized GH output and want a downstream tool.
IGF-1 LR3 doesn't go through the GH pathway at all — it's IGF-1 itself, modified to last longer in the body, injected directly. That makes it conceptually simple (skip the brain, act on the muscle directly) and practically more complex. Documented risks include hypoglycemia, because IGF-1 cross-activates the insulin receptor at high doses. Trial protocols and community guidance describe keeping fast-acting carbs accessible during use, and warn against combining IGF-1 with exogenous insulin without medical supervision.
For most users researching peptides for muscle, IGF-1 LR3 sits well past the point of diminishing returns. Its niche in community usage is the experienced user who has already maxed out a GHRH+GHRP stack, has clean labs, and wants additional tools — at which point a low-dose IGF-1 LR3 phase is sometimes added. Community usage as an entry-point peptide is rare.
Community reports cluster around three themes: vivid hand and forearm pumps within hours, durable strength gains over 4-6 weeks, and the consistent caution that hypoglycemia onsets faster than first-time users expect.
Best for: users who've explored the GH/IGF axis and want to test a completely different muscle pathway.
Follistatin works through different biology than everything else on this list. It binds and neutralizes myostatin — a protein the body produces specifically to limit muscle growth. Reduce myostatin signaling and the natural brakes on muscle ease. Gene-therapy delivery in nonhuman primate studies produced durable size and strength increases, but the human peptide-injection dataset is limited and shorter-term.
This is genuinely experimental territory. Community usage typically describes follistatin as a 4-week adjunct layered on top of a GHRH+GHRP stack — a separate lever rather than a replacement for the base stack. Long-term human safety data remains thin.
Community reports vary widely, which is itself a signal that responses are individual. Some users describe noticeable strength jumps within 2-3 weeks; others run a full vial and report no perceived change. Community usage clusters among users who already run a base GH stack — first-time users rarely choose follistatin as an entry point.
Community usage and trial-evidence patterns map cleanly onto reader profiles. Here's how the picks above tend to break down across common audiences:
Recomp-focused users with budget flexibility typically choose tesamorelin + ipamorelin. It has the strongest clinical evidence for combined fat-loss and lean-mass effects of any peptide on this list.
First-time GH-peptide users typically choose CJC-1295 + ipamorelin. It's cheaper, more widely available, and is the most common entry point in community sources.
Users over 45 prioritizing the gentlest option commonly settle on sermorelin + ipamorelin. Sermorelin has the longest clinical track record on this list and produces the smallest per-dose pulse.
Users who can't or won't inject are limited to MK-677 (oral) — the only non-injectable on this list with meaningful GH/IGF-1 elevation in trials. The trade-off is the side-effect profile (water retention, appetite, glucose drift) documented in published research.
Hard-gainers in a calorie surplus commonly pair CJC-1295 with GHRP-6 specifically for the appetite-stimulating effect of GHRP-6, which is documented in published research.
Users who've already run a base GHRH+GHRP stack sometimes layer IGF-1 LR3 or follistatin-344 on top as advanced tools. Community usage describes these as additions, not replacements.
Users sourcing through telehealth are typically limited to sermorelin or tesamorelin (the GHRH analogs commonly dispensed by compounding pharmacies). Community usage often describes pairing one of these with ipamorelin sourced separately to complete the stack.
For users optimizing fat loss alongside muscle, tesamorelin appears in both rankings — see best peptides for fat loss for the weight-loss-specific ranking.
What Trial and Community Data Describe as Signals of Effect
Three signals appear consistently in published research and community sources, in this order:
Weeks 1-2: Sleep changes first. This is the most consistently community-reported signal. Trial subjects and community sources commonly describe falling asleep faster, sleeping deeper, and reporting more vivid dreams within the first two weeks of GH peptide use. Community guidance treats absence of any sleep shift by day 14 as a flag for under-dosing, product degradation, or injection-timing issues.
Weeks 4-8: Bloodwork. IGF-1 is the most-tracked biomarker in both trials and community protocols — a working GHRH+GHRP stack typically raised IGF-1 30-60% from baseline in published studies. Trial data describe IGF-1 increases below 30% as suggesting under-dosing or product issues, and increases above 60% as the dose-reduction threshold most clinical protocols use. Trials also commonly tracked fasting glucose and HbA1c at 8-12 weeks; GH opposes insulin, and a subset of trial subjects developed measurable glucose elevation over time.
Weeks 6-12: Visible body composition. This is when the bloodwork translates to mirror-visible change. Trial subjects and community sources commonly describe waist tightening, fuller-looking muscles, and improved between-session recovery. Trial-reported lean-tissue gains in trained subjects on a full secretagogue cycle have typically clustered around 2-4 lb. Trial data does not support claims of steroid-scale transformations from secretagogue stacks alone.
Running GH peptides without bloodwork is functionally running them blind. The trial-and-community standard is baseline IGF-1 plus a 4-week recheck and 8-12 week metabolic panel — that's how published research designs measured efficacy, and it's what community sources commonly treat as the minimum monitoring set.
Bowers CY, et al. GH-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990;70(4):975-982.
Falutz J, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial. J Clin Endocrinol Metab. 2010;95(9):4291-4304.
Adrian S, et al. The growth hormone releasing hormone analogue, tesamorelin, decreases muscle fat and increases muscle area in adults with HIV. J Frailty Aging. 2019;8(3):154-159.
